Published Paper

Fioravanti P, Mascagni P, Besio E, Pincin C. Regulatory and QA challenges for approval and conduction of Pragmatic Clinical Trials in Europe under CTIS. Poster. 31° Congresso nazionale GIQAR.

Barbagallo S, Vaccari D, Enotarpi J, Fioravanti P. Digital health technologies in Europe and Italy. Profile of the clinical research on AI, deep learning and digital therapies. Poster. 31° Congresso nazionale GIQAR.

Fioravanti P, Besio E, Mascagni P, Pincin C. Digital therapies. Historical trend of the studies registered on ClinicalTrials.gov (1995-2023). Poster. 31° Congresso nazionale GIQAR

Kirchhof P, Bakhai A, de Asmundis C, de Groot JR, Deharo JC, Kelly P, Lopez-de-Sa E, Monteiro P, Fronk EM, Lamparter M, Laeis P, Smolnik R, Steffel J, Waltenberger J, Weiss TW, De Caterina R; ETNA-AF-Europe investigators. Long-term effectiveness and safety of edoxaban in patients with atrial fibrillation: 4-year data from the ETNA-AF-Europe study. Int J Cardiol. 2024 Apr 30;408:132118. doi: 10.1016/j.ijcard.2024.132118. Epub ahead of print. PMID: 38697397

Cemin R, Cappato R. Lessons derived from post authorisation safety studies (ETNA-AF and XANTUS) on once daily direct oral anticoagulants for atrial fibrillation. Int J Cardiol. 2024 Mar 1;398:131618. doi: 10.1016/j.ijcard.2023.131618. Epub 2023 Nov 27. PMID: 38030040.

Krucoff M, Spirito A, Baber U, Sartori S, Angiolillo DJ, Briguori C, Cohen DJ, Collier T, Dangas G, Dudek D, Escaned J, Gibson CM, Han YL, Huber K, Kastrati A, Kaul U, Kornowski R, Kunadian V, Vogel B, Mehta SR, Moliterno D, Sardella G, Shlofmitz RA, Sharma S, Steg PG, Pocock S, Mehran R. Ticagrelor with or without aspirin following percutaneous coronary intervention in high-risk patients with concomitant peripheral artery disease: A subgroup analysis of the TWILIGHT randomized clinical trial. Am Heart J. 2024 Jun;272:11-22. doi: 10.1016/j.ahj.2024.03.002. Epub 2024 Mar 6. PMID: 38458371.

Piaggesi A, et al. The Diabetic Foot Valley Project: bottom-up building of a community of practice for diabetic footcare in Tuscany. Journal of Wound Management. 2024;25(1):31-35.

Bedei A, Castellini L, De Grazia G, Silvani L, Remiddi S. Safety and Performance of an Artificial Tear Containing Arabinogalactan, Trehalose and Hyaluronic Acid in the Treatment of Dry Eye in Subjects with Signs of Inflammation of the Ocular Surface. Open Access Journal of Ophthalmology ISSN: 2578-465X. 20 Feb 2023.

Schnabel RB, Ameri P, Siller-Matula JM, Diemberger I, Gwechenberger M, Pecen L, Manu MC, Souza J, De Caterina R, Kirchhof P. Outcomes of patients with atrial fibrillation on oral anticoagulation with and without heart failure: the ETNA-AF-Europe registry. Europace. 2023 Aug 2;25(9):euad280. doi: 10.1093/europace/euad280. PMID: 37713182; PMCID: PMC10540669.

Patti G, Pecen L, Casalnuovo G, Manu MC, Kirchhof P, De Caterina R. Heterogeneity of outcomes within diabetic patients with atrial fibrillation on edoxaban: a sub-analysis from the ETNA-AF Europe registry. Clin Res Cardiol. 2023 Nov;112(11):1517-1528. doi: 10.1007/s00392-022-02080-5. Epub 2022 Aug 17. PMID: 35976428; PMCID: PMC10584730.

Baber U, Spirito A, Sartori S, Angiolillo DJ, Briguori C, Cohen DJ, Collier T, Dangas G, Dudek D, Escaned J, Gibson CM, Han YL, Huber K, Kastrati A, Kaul U, Kornowski R, Krucoff M, Kunadian V, Vogel B, Mehta SR, Moliterno D, Sardella G, Shlofmitz RA, Sharma S, Steg PG, Pocock S, Mehran R. Clinically Driven Revascularization in High-Risk Patients Treated With Ticagrelor Monotherapy After PCI: Insights from the Randomized TWILIGHT Trial. Am J Cardiol. 2023 Dec 1;208:16-24. doi: 10.1016/j.amjcard.2023.09.008. Epub 2023 Oct 6. PMID: 37806185.

Angiolillo DJ, Cao D, Sartori S, Baber U, Dangas G, Zhang Z, Vogel B, Kunadian V, Briguori C, Cohen DJ, Collier T, Dudek D, Gibson M, Gil R, Huber K, Kaul U, Kornowski R, Krucoff MW, Ielasi A, Stefanini GG, Pivato CA, Mehta S, Moliterno DJ, Ohman EM, Escaned J, Sardella G, Sharma SK, Shlofmitz R, Weisz G, Witzenbichler B, Steg PG, Pocock S, Mehran R. Dyspnea-Related Ticagrelor Discontinuation After Percutaneous Coronary Intervention. JACC Cardiovasc Interv. 2023 Oct 23;16(20):2514-2524. doi: 10.1016/j.jcin.2023.08.019. PMID: 37879803.

Mendieta G, Mehta S, Baber U, Angiolillo DJ, Briguori C, Cohen D, Collier T, Dangas G, Dudek D, Escaned J, Gil R, Vogel B, Cao D, Spirito A, Huber K, Kastrati A, Kaul U, Kornowski R, Krucoff MW, Kunadian V, Moliterno DJ, Ohman EM, Sardella G, Sartori S, Sharma S, Shlofmitz R, Steg PG, Han YL, Pocock S, Gibson CM, Mehran R. Bleeding and Ischemic Risks of Ticagrelor Monotherapy After Coronary Interventions. J Am Coll Cardiol. 2023 Aug 22;82(8):687-700. doi: 10.1016/j.jacc.2023.05.062. PMID: 37587580

Papavramidis T, Gentile I, Cattelan AM, Magnasco L, Viale P, Francisci D, Kofteridis DP, Tiseo G, Giamarellos-Bourboulis EJ, Lagi F, Pinna SM, D’Amico F, La Ferla L, Panagopoulos P, Gattuso G, Sipsas NV, Ruggieri A, Cattaneo A, Corio L, Comandini A, Mascagni P, Bassetti M. REDS study: Retrospective effectiveness study of dalbavancin and other standard of care of the same IV antibiotic class in patients with ABSSSI. Int J Antimicrob Agents. 2023 Apr;61(4):106746. doi: 10.1016/j.ijantimicag.2023.106746. Epub 2023 Feb 8. PMID: 36758778.

Ray KK, Haq I, Bilitou A, Manu MC, Burden A, Aguiar C, Arca M, Connolly DL, Eriksson M, Ferrières J, Laufs U, Mostaza JM, Nanchen D, Rietzschel E, Strandberg T, Toplak H, Visseren FLJ, Catapano AL; SANTORINI Study Investigators. Treatment gaps in the implementation of LDL cholesterol control among high- and very high-risk patients in Europe between 2020 and 2021: the multinational observational SANTORINI study. Lancet Reg Health Eur. 2023 Apr 5;29:100624. doi: 10.1016/j.lanepe.2023.100624. PMID: 37090089; PMCID: PMC10119631.

Orsi F, Maiettini D, Bagnardi V, Azziz R. Prospective Cohort Study Quantifying the Effect of the LevaLap 1.0 on the Distance between the Abdominal Wall and Intra-abdominal Viscera. J Minim Invasive Gynecol. 2023 Sep;30(9):748-756. doi: 10.1016/j.jmig.2023.05.004. Epub 2023 May 15. PMID: 37192723.

Fargnoli, M.C.; Bardazzi, F.; Bianchi, L.; Dapavo, P.; Fabbrocini, G.; Gisondi, P.; Micali, G.; Offidani, A.M.; Pellacani, G.; Skroza, N.; et al. Brodalumab for the Treatment of Moderate-to-Severe Psoriasis: An Expert Delphi Consensus Statement. J. Clin. Med. 2023, 12, 3545.

Fioravanti P, Mascagni P, Barbagallo S. Clinical research on skin ulcers in Italy. Historical trend in the twenty-year period 2003-2022 and prospects for industrial investments in research in our country. XVII Nazional Congress AIUC October 2023 (poster n-180).

Giordano P, Pollio B, Sottilotta G, Biasoli C, Daniele F, De Cristofaro R, Peyvandi F, Villa MR, Castaman G; IDEAL Study Group. Pattern of use and clinical outcomes with rIX-FP in pediatric/adolescent patients with haemophilia B in Italy: Results from IDEAL real-world study. Eur J Haematol. 2023 May;112(5):765-775.

Stürzebecher PE, Tünnemann-Tarr A, Tuppatsch K, Laufs U. Behandlung und LDL-Cholesterin-Einstellung von Patienten mit hohem und sehr hohem kardiovaskulärem Risiko in Deutschland und im europäischen Vergleich – Daten des SANTORINI-Registers [Treatment and LDL cholesterol adjustment in patients with high and very high cardiovascular risk in Germany compared with Europe – data from the SANTORINI registry]. Dtsch Med Wochenschr. 2023 Apr;148(9):55-64.

Bedei A, Castellini L, De Grazia G, Silvani L, Remiddi S. Safety and Performance of an Artificial Tear Containing Arabinogalactan, Trehalose and Hyaluronic Acid in the Treatment of Dry Eye in Subjects with Signs of Inflammation of the Ocular Surface. Open Access Journal of Ophthalmology ISSN: 2578-465X. 20 Feb 2023.

Tagliaferri A, Molinari AC, Peyvandi F, Coppola A, Demartis F, Biasoli C, Borchiellini A, Cultrera D, De Cristofaro R, Daniele F, Giordano P, Marchesini E, Margaglione M, Marino R, Pollio B, Radossi P, Santoro C, Santoro RC, Siragusa S, Sottilotta G, Tosetto A, Piscitelli L, Villa MR, Zanon E, Finardi A, Schiavetti I, Vaccari D, Castaman G. IDEAL study: A real-world assessment of pattern of use and clinical outcomes with recombinant coagulation factor IX albumin fusion protein (rIX-FP) in patients with haemophilia B in Italy.Haemophilia. 2022 Nov 24.

Picardo M, Cardinali C, La Placa M, Lewartowska-Białek A, Lora V, Micali G, Montisci R, Morbelli L, Nova A, Parodi A, Reich A, Sebastian M, Turek-Urasińska K, Weirich O, Zdybski J, Zouboulis CC; GEDACNE Study Group. Efficacy and safety of N-acetyl-GED-0507-34-LEVO gel in patients with moderate-to severe facial acne vulgaris: a phase IIb randomized double-blind, vehicle-controlled trial. Br J Dermatol. 2022 Oct;187(4):507-514.

Spada F, Bossi P, Caracò C, Sileni VC, Dei Tos AP, Fazio N, Grignani G, Maio M, Quaglino P, Queirolo P, Ascierto PA; DELPHI Panel Members. Nationwide multidisciplinary consensus on the clinical management of Merkel cell carcinoma: a Delphi panel. J Immunother Cancer. 2022 Jun;10(6).

Prignano F, Brunasso AMG, Fabbrocini G, Argenziano G, Bardazzi F, Borroni RG, Burlando M, Cagni AE, Campione E, Cinotti E, Cuccia A, Dastoli S, De Pasquale R, De Simone C, Di Lernia V, Dini V, Fargnoli MC, Faure E, Giacchetti A, Giofrè C, Girolomoni G, Lasagni C, Lembo S, Loconsole F, Montesu MA, Pella P, Pigatto P, Richetta AG, Stroppiana E, Venturini M, Zichichi L, Piaserico S. Sharing Patient and Clinician Experiences of Moderate-to-Severe Psoriasis: A Nationwide Italian Survey and Expert Opinion to Explore Barriers Impacting upon Patient Wellbeing. J Clin Med. 2022 May 16-

Patti G, Parato VM, Cavallari I, Calabrò P, Russo V, Renda G, Gragnano F, Pengo V, D’Onofrio A, Grimaldi M, De Caterina R. A Prospective Study to Evaluate the Effectiveness of Edoxaban for the Resolution of Left Atrial Thrombosis in Patients with Atrial Fibrillation. J Clin Med. 2022 Mar 31;11(7):1945.

Ruggeri A et al. Analysis of the Clinical Management of the patients with ABSSSI from the data of the REDS Study (Retrospective Effectiveness study of Dalbavancin and other Standard of Care of the same class in patients with ABSSSI ) with abstract ID 04340 was submitted to ECCMID 2022 (32nd European Congress of Clinical Microbiology and Infectious Diseases).

Unverdorben M, von Heymann C, Santamaria A, Saxena M, Vanassche T, Wilkins R, Jin J, Chen C, Colonna P. Thromboembolic and bleeding risks in edoxaban patients with pacemaker and cardiac monitoring procedures: Outcomes of the Global EMIT program. Pacing Clin Electrophysiol. 2022 Jan;45(1). Pub Date: 2021-10-18 , DOI:10.1111/pace.14381.

Kirchhof P, Pecen L, Bakhai A, de Asmundis C, de Groot JR, Deharo JC, Kelly P, Levy P, Lopez-de-Sa E, Monteiro P, Steffel J, Waltenberger J, Weiss TW, Laeis P, Manu MC, Souza J, De Caterina R. Edoxaban for stroke prevention in atrial fibrillation and age-adjusted predictors of clinical outcomes in routine clinical care. Eur Heart J Cardiovasc Pharmacother. 2022 Dec 15;9(1):47-57. doi: 10.1093/ehjcvp/pvac042. PMID: 35881467; PMCID: PMC9753092.

Diemberger I, Fumagalli S, Mazzone AM, Bakhai A, Reimitz PE, Pecen L, Manu MC, Gordillo de Souza JA, Kirchhof P, De Caterina R. Perceived vs. objective frailty in patients with atrial fibrillation and impact on anticoagulant dosing: an ETNA-AF-Europe sub-analysis. Europace. 2022 Oct 13;24(9):1404-1411. doi: 10.1093/europace/euac004. PMID: 35512229; PMCID: PMC9559908.

Löffler MW, Gori S, Izzo F, Mayer-Mokler A, Ascierto PA, Königsrainer A, Ma YT, Sangro B, Francque S, Vonghia L, Inno A, Avallone A, Ludwig J, Alcoba DD, Flohr C, Aslan K, Mendrzyk R, Schuster H, Borrelli M, Valmori D, Chaumette T, Heidenreich R, Gouttefangeas C, Forlani G, Tagliamonte M, Fusco C, Penta R, Iñarrairaegui M, Gnad-Vogt U, Reinhardt C, Weinschenk T, Accolla RS, Singh-Jasuja H, Rammensee HG, Buonaguro L. Phase I/II Multicenter Trial of a Novel Therapeutic Cancer Vaccine, HepaVac-101, for Hepatocellular Carcinoma. Clin Cancer Res. 2022 Jun 13;28(12):2555-2566. doi: 10.1158/1078-0432.CCR-21-4424. PMID: 35421231.

Kunadian V, Baber U, Pivato CA, Cao D, Dangas G, Sartori S, Zhang Z, Angiolillo DJ, Briguori C, Cohen DJ, Collier T, Dudek D, Gibson M, Gil R, Huber K, Kaul U, Kornowski R, Krucoff MW, Dehghani P, Mehta S, Moliterno DJ, Ohman EM, Escaned J, Sardella G, Sharma SK, Shlofmitz R, Weisz G, Witzenbichler B, Džavík V, Gurbel P, Hamm CW, Henry T, Kastrati A, Marx SO, Oldroyd K, Steg PG, Pocock S, Mehran R. Bleeding and Ischemic Outcomes With Ticagrelor Monotherapy According to Body Mass Index. JACC Cardiovasc Interv. 2022 Oct 10;15(19):1948-1960. doi: 10.1016/j.jcin.2022.07.039. PMID: 36202563.

Dehghani P, Cao D, Baber U, Nicolas J, Sartori S, Pivato CA, Zhang Z, Dangas G, Angiolillo DJ, Briguori C, Cohen DJ, Collier T, Dudek D, Gibson M, Gil R, Huber K, Kaul U, Kornowski R, Krucoff MW, Kunadian V, Mehta S, Moliterno DJ, Ohman EM, Escaned J, Sardella G, Sharma SK, Shlofmitz R, Weisz G, Witzenbichler B, Pocock S, Mehran R. Ticagrelor monotherapy after PCI in patients with concomitant diabetes mellitus and chronic kidney disease: TWILIGHT DM-CKD. Eur Heart J Cardiovasc Pharmacother. 2022 Sep 29;8(7):707-716. doi: 10.1093/ehjcvp/pvac016. PMID: 35325085.

Chiarito M, Baber U, Cao D, Sharma SK, Dangas G, Angiolillo DJ, Briguori C, Cohen DJ, Dudek D, Džavík V, Escaned J, Gil R, Hamm CW, Henry T, Huber K, Kastrati A, Kaul U, Kornowski R, Krucoff M, Kunadian V, Mehta SR, Moliterno D, Ohman EM, Oldroyd K, Sardella G, Zhongjie Z, Sartori S, Stefanini G, Shlofmitz R, Steg PG, Weisz G, Witzenbichler B, Han YL, Pocock S, Gibson CM, Mehran R. Ticagrelor Monotherapy After PCI in High-Risk Patients With Prior MI: A Prespecified TWILIGHT Substudy. JACC Cardiovasc Interv. 2022 Feb 14;15(3):282-293. doi: 10.1016/j.jcin.2021.11.005. Epub 2022 Jan 12. PMID: 35033468.

Ricci E. Pittarello M. Wound bed preparation with hypochlorous acid oxidising solution and standard of care: a prospective case series. Journal of Wound CareVol. 30, No. 10 13 Oct 2021.

Carpenedo M, Baldacci E, Baratè C, Borchiellini A, Buccisano F, Calvaruso G, Chiurazzi F, Fattizzo B, Giuffrida G, Rossi E, Palandri F, Scalzulli PR, Siragusa SM, Vitucci A, Zaja F. Second-line administration of thrombopoietin receptor agonists in immune thrombocytopenia: Italian Delphi-based consensus recommendations. Ther Adv Hematol. 2021 Oct 9.

Doria M, Careddu D, Iorio R, Verrotti A, Chiappini E, Barbero GM, Ceschin F, Dell’Era L, Fabiano V, Mencacci M, Carlomagno F, Libranti M, Mazzone T, Vitale A. Paracetamol and Ibuprofen in the Treatment of Fever and Acute Mild-Moderate Pain in Children: Italian Experts’ Consensus Statements. Children (Basel). 2021 Sep 30;8(10):873.

M. M. J. Van Rooijen, T. Tollens, L. N. Jørgensen, T. S. de Vries Reilingh, G. Piessen, F. Köckerling, M. Miserez, A. C. J. Windsor, F. Berrevoet, R. H. Fortelny, B. Dousset, G. Woeste, H. L. van Westreenen, F. Gossetti, J. F. Lange, G. W. M. Tetteroo, A. Koch, J. Jeekel. Slowly resorbable biosynthetic mesh: 2‑year results in VHWG grade 3 hernia repair. Hernia 2021 July 19 –

de Groot JR, Weiss TW, Kelly P, Monteiro P, Deharo JC, de Asmundis C, López-de-Sá E, Waltenberger J, Steffel J, Levy P, Bakhai A, Zierhut W, Laeis P, Manu MC, Reimitz PE, De Caterina R, Kirchhof P. Edoxaban for stroke prevention in atrial fibrillation in routine clinical care: 1-year follow-up of the prospective observational ETNA-AF-Europe study. Eur Heart J Cardiovasc Pharmacother. 2021 Apr 9;7.

Fazio G, Squizzato A, Mazzetti M, Mannarini A, Fischetti A, Colonna P. Sospensione perioperatoria di edoxaban associata a basso rischio di emorragia e tromboembolia: i dati italiani dello studio EMIT-AF/VTE. G Ital Cardiol 2021;22(1):70-79.

Cohen A, Nakamura M, Chiu KM, Choi WI, Reimitz PE, Jiang W, Chen C, Unverdorben M, Agnelli G. Active Cancer and Venous Thromboembolism: Safety and Effectiveness of Edoxaban in Patients from the Noninterventional Global ETNA-VTE Program. Meeting: ISTH 2021 Congress Abstract Number: LPB0090.

De Caterina R, Kim YH, Koretsune Y, Wang CC, Yamashita T, Chen C, Reimitz PE, Unverdorben M, Kirchhof P. Safety and Effectiveness of Edoxaban in Atrial Fibrillation Patients in Routine Clinical Practice: One-Year Follow-Up from the Global Noninterventional ETNA-AF Program. J Clin Med. 2021 Feb 3;10(4):573. doi: 10.3390/jcm10040573. PMID: 33546442; PMCID: PMC7913627.

Chao TF, Unverdorben M, Kirchhof P, Koretsune Y, Yamashita T, Crozier RA, Pecen L, Chen C, Borrow AP, De Caterina R. Prescribing Patterns and Outcomes of Edoxaban in Atrial Fibrillation: One-Year Data from the Global ETNA-AF Program. J Clin Med. 2023 Feb 27;12(5):1870. doi: 10.3390/jcm12051870. PMID: 36902656; PMCID: PMC10003604.

Boriani G, De Caterina R, Manu MC, Souza J, Pecen L, Kirchhof P. Impact of Weight on Clinical Outcomes of Edoxaban Therapy in Atrial Fibrillation Patients Included in the ETNA-AF-Europe Registry. J Clin Med. 2021 Jun 29;10(13):2879. doi: 10.3390/jcm10132879. PMID: 34209595; PMCID: PMC8269173.

Escaned J, Cao D, Baber U, Nicolas J, Sartori S, Zhang Z, Dangas G, Angiolillo DJ, Briguori C, Cohen DJ, Collier T, Dudek D, Gibson M, Gil R, Huber K, Kaul U, Kornowski R, Krucoff MW, Kunadian V, Mehta S, Moliterno DJ, Ohman EM, Oldroyd KG, Sardella G, Sharma SK, Shlofmitz R, Weisz G, Witzenbichler B, Pocock S, Mehran R. Ticagrelor monotherapy in patients at high bleeding risk undergoing percutaneous coronary intervention: TWILIGHT-HBR. Eur Heart J. 2021 Dec 1;42(45):4624-4634. doi: 10.1093/eurheartj/ehab702. PMID: 34662382.

Stefanini GG, Briguori C, Cao D, Baber U, Sartori S, Zhang Z, Dangas G, Angiolillo DJ, Mehta S, Cohen DJ, Collier T, Dudek D, Escaned J, Gibson CM, Gil R, Huber K, Kaul U, Kornowski R, Krucoff MW, Kunadian V, Moliterno DJ, Ohman EM, Oldroyd KG, Sardella G, Sharma SK, Shlofmitz R, Weisz G, Witzenbichler B, Pocock S, Mehran R. Ticagrelor monotherapy in patients with chronic kidney disease undergoing percutaneous coronary intervention: TWILIGHT-CKD. Eur Heart J. 2021 Dec 1;42(45):4683-4693. doi: 10.1093/eurheartj/ehab533. PMID: 34423374.
13. Angiolillo DJ, Cao D, Baber U, Sartori S, Zhang Z, Dangas G, Mehta S, Briguori C, Cohen DJ, Collier T, Dudek D, Escaned J, Gibson CM, Gil R, Huber K, Kaul U, Kornowski R, Krucoff MW, Kunadian V, Moliterno DJ, Ohman EM, Oldroyd K, Sardella G, Sharma SK, Shlofmitz R, Weisz G, Witzenbichler B, Pocock S, Mehran R. Impact of Age on the Safety and Efficacy of Ticagrelor Monotherapy in Patients Undergoing PCI. JACC Cardiovasc Interv. 2021 Jul 12;14(13):1434-1446. doi: 10.1016/j.jcin.2021.04.043. PMID: 34238553.

Vogel B, Baber U, Cohen DJ, Sartori S, Sharma SK, Angiolillo DJ, Farhan S, Goel R, Zhang Z, Briguori C, Collier T, Dangas G, Dudek D, Escaned J, Gil R, Han YL, Kaul U, Kornowski R, Krucoff MW, Kunadian V, Mehta SR, Moliterno D, Ohman EM, Sardella G, Witzenbichler B, Gibson CM, Pocock S, Huber K, Mehran R. Sex Differences Among Patients With High Risk Receiving Ticagrelor With or Without Aspirin After Percutaneous Coronary Intervention: A Subgroup Analysis of the TWILIGHT Randomized Clinical Trial. JAMA Cardiol. 2021 Sep 1;6(9):1032-1041. doi: 10.1001/jamacardio.2021.1720. PMID: 33991416; PMCID: PMC8124295.

Ray KK, Haq I, Bilitou A, Aguiar C, Arca M, Connolly DL, Eriksson M, Ferrières J, Hildebrandt P, Laufs U, Mostaza JM, Nanchen D, Rietzschel E, Strandberg T, Toplak H, Visseren FLJ, Catapano AL. Evaluation of contemporary treatment of high- and very high-risk patients for the prevention of cardiovascular events in Europe – Methodology and rationale for the multinational observational SANTORINI study. Atheroscler Plus. 2021 Aug 13;43:24-30. doi: 10.1016/j.athplu.2021.08.003. PMID: 36644508; PMCID: PMC9833224.

Cohen AT, Hoffmann U, Hainaut P, Gaine S, Ay C, Coppens M, Schindewolf M, Jimenez D, Brüggenjürgen B, Levy P, Laeis P, Eva-Maria Fronk EM, Zierhut W, Thomas Malzer T, Manu MC, Reimitz PE, Bramlage P , Agnelli G. ETNA-VTE-Europe investigators. ETNA VTE Europe: A contemporary snapshot of patients treated with edoxaban in clinical practice across eight European countries. Eur J Intern Med . 2020 Dec;82:48-55.

Cappelletti M, Tognon E, Vona L, Basello K, Costanzi A, Speciani MC, Speciani AF. Food-specific serum IgG and ymptom reduction with a personalized, unrestricted-calorie diet of six weeks in Irritable Bowel Syndrome (IBS). Nutr Metab (Lond). 2020 Dec 1;17(1):101.

Falconi M, Fazio N, Ferone D, Versari A. Use of octreotide long acting repeatable (LAR) as second-line therapy in advanced neuroendocrine tumors in different clinical settings: an Italian Delphi survey. Journal: Expert Opinion on Pharmacotherapy. Published online: 29 Sep 2020.

Saccarello A, Montarsolo P, Massardo I, Picciotto R, Pedemonte A, Castagnaro R, Brasesco PC, Guida V, Picco P, Fioravanti P, Montisci R, Schiavetti I, Vanelli A. Oral Administration of S-Adenosylmethionine (SAMe) and Lactobacillus Plantarum HEAL9 Improves the Mild-To-Moderate Symptoms of Depression: A Randomized, Double-Blind, Placebo-Controlled Study. Prim Care Companion CNS Disord 2020;22(0):19m02578.

Samama M, Laporte S, Rosencher N, Girard P, Llau J, Mouret P, Fisher W, Martínez-Martín J, Duverger D, Deygas B, Presles E, Cucherat M, Mismetti P for the PRONOMOS Investigator. Rivaroxaban or Enoxaparin in Nonmajor Orthopedic Surgery. N Engl J Med. 2020 Mar 29.

Fioravanti P., Champiot M, Vaccari D, Besio E, Montisci R. Trends in clinical research on and with Software as Medical Devices (SaMD). ICPM/SIMeF conference, Rome 25-27 March 2020.

Fioravanti P., Champiot M, Zurita R, Mascagni P, Vacccari D. Profile of the protocols of interventional studies using Software as Medical Devices (SaMD). ICPM/SIMeF conference, Rome 25-27 March 2020.

Fioravanti P, Vaccari D, Consiglieri C, Pincin C, Besio E. Smoking cessation: clinical development of dedicated SaMDs (Software as Medical Devices). ICPM/SIMeF conference, Rome 25-27 March 2020.

F. Salaffi, S. Farah, M. Di Carlo, L. Sinigaglia, M. Galeazzi, R. Gerli, M. Sonnati, V. Giorgi, P. Sarzi-Puttini on behalf of the Italian Society of Rheumatology (SIR), M. Masullo on behalf of the Ministero della Salute – Direzione Generale della Programmazione Sanitaria, Roma, Italy. The Italian Fibromyalgia Registry: a new way of using routine real-world data concerning patient-reported disease status in healthcare research and clinical practice. Clin Exp Rheumatol 2020; 38 (Suppl. 123).

Ameri P, Riva L, Toma M, Di Pasquale G, De Caterina R. [One-year follow-up of Italian patients with atrial fibrillation treated with edoxaban in ETNA-AF Europe] G Ital Cardiol (Rome). 2020 Jul; 21(7): 546-557.

Riva L, Diemberger I, Di Pasquale G, Attena E, Sangiuolo R, De Caterina R. ETNA-AF study: Italian baseline data and comparison with the European population in atrial fibrillation patients treated with edoxaban. G Ital Cardiol (Rome). 2020 Feb;21(2):141-151.

Agnelli G, Hoffmann U, Hainaut P, Gaine S, Ay C, Coppens M, Schindewolf M, Jimenez D, Brüggenjürgen B, Levy P, Laeis P, Fronk EM, Zierhut W, Malzer T, Manu MC, Reimitz PE, Bramlage P, Cohen AT; ETNA-VTE-Europe investigators. ETNA-VTE Europe: Benefits and risks of venous thromboembolism treatment using edoxaban in the first 3 months. Thromb Res. 2020 Dec;196:297-304. doi: 10.1016/j.thromres.2020.09.001. Epub 2020 Sep 12. PMID: 32950897.

Baber U, Dangas G, Angiolillo DJ, Cohen DJ, Sharma SK, Nicolas J, Briguori C, Cha JY, Collier T, Dudek D, Džavik V, Escaned J, Gil R, Gurbel P, Hamm CW, Henry T, Huber K, Kastrati A, Kaul U, Kornowski R, Krucoff M, Kunadian V, Marx SO, Mehta S, Moliterno D, Ohman EM, Oldroyd K, Sardella G, Sartori S, Shlofmitz R, Steg PG, Weisz G, Witzenbichler B, Han YL, Pocock S, Gibson CM, Mehran R. Ticagrelor alone vs. ticagrelor plus aspirin following percutaneous coronary intervention in patients with non-ST-segment elevation acute coronary syndromes: TWILIGHT-ACS. Eur Heart J. 2020 Oct 1;41(37):3533-3545. doi: 10.1093/eurheartj/ehaa670. PMID: 33085967.

Baber U, Chandiramani R, Mehta SR, Sartori S, Zhang Z, Claessen BE, Briguori C, Sharma S, Dangas G, Mehran R. Safety and efficacy of the bioabsorbable polymer everolimus-eluting stent versus durable polymer drug-eluting stents in high-risk patients undergoing PCI: TWILIGHT-SYNERGY. Catheter Cardiovasc Interv. 2021 Jan 1;97(1):63-71. doi: 10.1002/ccd.28995. Epub 2020 Jun 10. PMID: 32406998.

Dangas G, Baber U, Sharma S, Giustino G, Mehta S, Cohen DJ, Angiolillo DJ, Sartori S, Chandiramani R, Briguori C, Dudek D, Escaned J, Huber K, Collier T, Kornowski R, Kunadian V, Kaul U, Oldroyd K, Sardella G, Shlofmitz R, Witzenbichler B, Ya-Ling H, Pocock S, Gibson CM, Mehran R. Ticagrelor With or Without Aspirin After Complex PCI. J Am Coll Cardiol. 2020 May 19;75(19):2414-2424. doi: 10.1016/j.jacc.2020.03.011. Epub 2020 Mar 30. PMID: 32240761.

Angiolillo DJ, Baber U, Sartori S, Briguori C, Dangas G, Cohen DJ, Mehta SR, Gibson CM, Chandiramani R, Huber K, Kornowski R, Weisz G, Kunadian V, Oldroyd KG, Ya-Ling H, Kaul U, Witzenbichler B, Dudek D, Sardella G, Escaned J, Sharma S, Shlofmitz RA, Collier T, Pocock S, Mehran R. Ticagrelor With or Without Aspirin in High-Risk Patients With Diabetes Mellitus Undergoing Percutaneous Coronary Intervention. J Am Coll Cardiol. 2020 May 19;75(19):2403-2413. doi: 10.1016/j.jacc.2020.03.008. Epub 2020 Mar 30. PMID: 32240760.

Cappelletti M, Tognon E, Vona L, Basello K, Costanzi A, Speciani MC, Speciani AF. Food-specific serum IgG and symptom reduction with a personalized, unrestricted-calorie diet of six weeks in Irritable Bowel Syndrome (IBS). Nutr Metab (Lond). 2020 Dec 1;17(1):101. doi: 10.1186/s12986-020-00528-x. PMID: 33292297; PMCID: PMC7708901.

A. Tagliaferri, J. Oldenburg, K. Peerlinck, G. Castaman. Real‐world Use of Recombinant Factor IX Albumin Fusion Protein (rIX‐FP) in Patients with Hemophilia B: A Multinational Prospective, Non‐interventional, Post‐marketing Surveillance Study. Res Pract Thromb Haemost. 2019;3(Suppl. 1):1–891 [Abstracts of the XXVII Congress of the International Society on Thrombosis and Haemostasis. PB0281].

De Caterina R, Kelly P, Monteiro P, Deharo JC, de Asmundis C, López-de-Sá E, Weiss TW, Waltenberger J, Steffel J, de Groot JR, Levy P, Bakhai A, Zierhut W, Laeis P, Kerschnitzki M, Reimitz PE, Kirchhof P; ETNA-AF-Europe investigators. Characteristics of patients initiated on edoxaban in Europe: baseline data from edoxaban treatment in routine clinical practice for patients with atrial fibrillation (AF) in Europe (ETNA-AF-Europe). BMC Cardiovasc Disord. 2019 Jul 12;19(1):165.

Marchesoni A, D’Angelo S, Anzidei M, Bortolotti R, Cantini F, Caramella D, Carotti M, Chimenti M, Delle Sedie A, Egan CG, Fabbroni M, Frediani B, Fusaro E, Galeazzi M, Gallazzi MB, Gentileschi S, Gentili F, Gerli R1 Gilio M, Iannone F, La Paglia E, Lubrano E, Macarini L, Olivieri I, Pellerito R, Ramonda R, Salvarani C, Scarano E, Scarpa R, Spaggiari L, Spanò A, Zawaideh JP, Mazzei MA; SHARE Study Group. Radiologist-rheumatologist multidisciplinary approach in the management of axial spondyloarthritis: a Delphi consensus statement. Clin Exp Rheumatol. 2019 Jul-Aug;37(4):575-584. –

Kwan P. Commentary on “Do neurologists agree in diagnosing drug resistance in adults with focal epilepsy?” Epilepsia. 2019 Jun;60(6):1124-1125.

Mula M, Zaccara G, Galimberti CA, Ferrò B, Canevini MP, Mascia A, Mecarelli O, Michelucci R, Pisani LR, Specchio LM, Striano S, Perucca E. Validated outcome of treatment changes according to International League Against Epilepsy criteria in adults with drug-resistant focal epilepsy. Epilepsia. 2019 Jun;60(6):1114-1123.

Vedovati MC, Giustozzi M, Becattini C. Venous thromboembolism and cancer: Current and future role of direct-acting oral anticoagulants. Thromb Res. 2019 May;177:33-41.

Lavalle C, Straito M, Caroli A, Piro A, Giunta G, Mariani MV, Fedele F. Rivaroxaban in atrial fibrillation cardioversion: an update. Ther Clin Risk Manag. 2019 May 2;15:613-626.

Rohla M, Weiss TW, Pecen L, Patti G, Siller-Matula JM, Schnabel RB, Schilling R, Kotecha D, Lucerna M, Huber K, De Caterina R, Kirchhof P. Risk factors for thromboembolic and bleeding events in anticoagulated patients with atrial fibrillation: the prospective, multicentre observational PREvention oF thromboembolic events – European Registry in Atrial Fibrillation (PREFER in AF).BMJ Open. 2019 Mar 30;9(3):e022478.

De Caterina R, Kelly P, Monteiro P, Deharo JC, de Asmundis C, López-de-Sá E, Weiss TW, Waltenberger J, Steffel J, de Groot JR, Levy P, Bakhai A, Zierhut W, Laeis P, Reimitz PE, Kirchhof P; ETNA-AF-Europe investigators. Design and rationale of the Edoxaban Treatment in routiNe clinical prActice for patients with Atrial Fibrillation in Europe (ETNA-AF-Europe) study. J Cardiovasc Med (Hagerstown). 2019 Feb;20(2):97-104.

Zaccara G, Mula M, Ferrò B, Consoli D, Elia M, Giallonardo AT, Iudice A, La Neve A, Meletti S, Tinuper P, Zummo L, Perucca E. Do neurologists agree in diagnosing drug resistance in adults with focal epilepsy? Epilepsia. 2019 Jan;60(1):175-183.

Remitz A, De Pità O, Mota A, Serra-Baldrich E, Vakirlis E, Kapp A. Position statement: topical calcineurin inhibitors in atopic dermatitis. J Eur Acad Dermatol Venereol. 2018 Dec;32(12):2074-2082. –

Patti G, Pecen L, Lucerna M, Huber K, Rohla M, Renda G, Siller-Matula J, Schnabel RB, Cemin R, Kirchhof P, De Caterina R. Outcomes of anticoagulated patients with atrial fibrillation treated with or without antiplatelet therapy – A pooled analysis from the PREFER in AF and PREFER in AF PROLONGATON registries. Int J Cardiol. 2018 Nov 1;270:160-166.

Olivieri I, Accorinti M, Abicca I, Bisceglia P, Cimino L, Latanza L, Leccese P, Lubrano E, Marchesoni A, Miserocchi E, Neri P, Salvarani C, Scarpa R, D’Angelo S; CORE Study Group. Standardization of red flags for referral to rheumatologists and ophthalmologists in patients with rheumatic diseases and ocular involvement: a consensus statement. Rheumatol Int. 2018 Sep;38(9):1727-1734.

Verze P, Arcaniolo D. Imbimbo C, Cai T, Venturino L, Spirito L, Califano G, La Rocca R, Mirone V. General and sex profile of women with partner affected by premature ejaculation: results of a large observational, non-interventional, cross-sectional, epidemiological study (IPER-F).. Andrology. 2018 Sep;6(5):714-719.

Colonna P, von Heymann C, Santamaria A, Matsushita Y, Unverdorben M. Edoxaban Management in Diagnostic and Therapeutic Procedures (EMIT-AF/VTE)-Trial design. Clin Cardiol. 2018:1-7.

Siller-Matula JM, Pecen L, Patti G, Lucerna M, Kirchhof P, Lesiak M, Huber K, Verheugt FWA, Lang IM, Renda G, Schnabel RB, Wachter R, Kotecha D, Sellal JM, Rohla M, Ricci F, De Caterina R; TEAM in AF group. Heart failure subtypes and thromboembolic risk in patients with atrial fibrillation: The PREFER in AF – HF substudy. Int J Cardiol. 2018 Aug 15;265:141-147.

Cohen AT, Ay C, Hainaut P, Décousus H, Hoffmann U, Gaine S, Coppens M, da Silva PM, Jimenez D, Amann-Vesti B, Brüggenjürgen B, Levy P, Bastida JL, Vicaut E, Laeis P, Fronk EM, Zierhut W, Malzer T, Bramlage P, Agnelli G; ETNA-VTE-Europe investigators. Correction to: Design and rationale of the non-interventional, edoxaban treatment in routiNe clinical prActice in patients with venous ThromboEmbolism in Europe (ETNA-VTE-Europe) study. Thromb J. 2018 May 31;16:18.

Cohen AT, Ay C, Hainaut P, Décousus H, Hoffmann U, Gaine S, Coppens M, da Silva PM, Castro DJ, Amann-Vesti B, Brüggenjürgen B, Levy P, Bastida JL, Vicaut E, Laeis P, Fronk EM, Zierhut W, Malzer T, Bramlage P, Agnelli G; ETNA-VTE-Europe investigators. Design and rationale of the non-interventional, edoxaban treatment in routiNe clinical prActice in patients with venous ThromboEmbolism in Europe (ETNA-VTE-Europe) study. Thromb J. 2018 May 1;16:9.

Verze P, Arcaniolo D, Palmieri A, Cai T, La Rocca R, Franco M, Venturino L, De Sio M, Mirone V. Premature Ejaculation Among Italian Men: Prevalence and Clinical Correlates From an Observational, Non-Interventional, Cross-Sectional, Epidemiological Study (IPER). Sex Med. 2018 May 23.

Rizzello F, Olivieri I, Armuzzi A, Ayala F, Bettoli V, Bianchi L, Cimino L, Costanzo A, Cristaudo A, D’Angelo S, Daperno M, Fostini AC, Galeazzi M, Gilio M, Gionchetti P, Gisondi P, Lubrano E, Marchesoni A, Offidani A, Orlando A, Pugliese D, Salvarani C, Scarpa R, Vecchi M, Girolomoni G. Multidisciplinary Management of Spondyloarthritis-Related Immune-Mediated Inflammatory Disease. Adv Ther. 2018 Apr;35(4):545-562.

Schnabel R, Pecen L, Engler D, Lucerna M, Sellal JM, Ojeda FM, De Caterina R, Kirchhof P. Atrial fibrillation patterns are associated with arrhythmia progression and clinical outcomes. Heart. 2018 Mar 17.

Figueira J, Fletcher E, Massin P, Silva R, Bandello F, Midena E, Varano M, Sivaprasad S, Eleftheriadis H, Menon G, Amaro M, Ayello Scheer S, Creuzot-Garcher C, Nascimento J, Alves D, Nunes S, Lobo C, Cunha-Vaz J; EVICR.net Study Group. Ranibizumab Plus Panretinal Photocoagulation versus Panretinal Photocoagulation Alone for High-Risk Proliferative Diabetic Retinopathy (PROTEUS Study). Ophthalmology. 2018 May;125(5):691-700.

De Caterina R, Brüggenjürgen B, Darius H, Köhler S, Lucerna M, Pecen L, Renda G, Schilling RJ, Schliephacke T, Zamorano JL, Le Heuzey JY, Kirchhof P. Quality of life and patient satisfaction in patients with atrial fibrillation on stable vitamin K antagonist treatment or switched to a non-vitamin K antagonist oral anticoagulant during a 1-year follow-up: A PREFER in AF Registry substudy. Arch Cardiovasc Dis. 21 Sep 2017, 111(2):74-84

Bauersachs R, Agnelli G, Gitt AK, Monreal M, Mismetti P, Willich SN, Laeis P, Fronk EM, Bramlage P, Cohen AT; PREFER in VTE Scientific Steering Committee. The role of heparin lead-in in the real-world management of acute venous thromboembolism: The PREFER in VTE registry. Thromb Res. 2017 Sep;157:181-188.

Franchi C, Miracapillo A, Narcisi A, Zichichi L. Therapeutic adherence in mild-to-moderate psoriasis: practical indications by a Delphi Panel.. Therapy perspectives 2017 Sep. Year XX, N. 13.

Patti G, Lucerna M, Pecen L, Siller-Matula JM, Cavallari I, Kirchhof P, De Caterina R. Thromboembolic Risk, Bleeding Outcomes and Effect of Different Antithrombotic Strategies in Very Elderly Patients With Atrial Fibrillation: A Sub-Analysis From the PREFER in AF (PREvention oF Thromboembolic Events-European Registry in Atrial Fibrillation). J Am Heart Assoc. 2017 Jul 23;6(7)

Cohen AT, Gitt AK, Bauersachs R, Fronk EM, Laeis P, Mismetti P, Monreal M, Willich SN, Bramlage P, Agnelli G, PREFER in VTE Scientific Steering Committee And The Prefer In Vte Investigators OBOT. The management of acute venous thromboembolism in clinical practice. Results from the European PREFER in VTE Registry. Thromb Haemost. 2017 Jun 27;117(7):1326-1337.

Antonini A, Barone P, Bonuccelli U et al. ICARUS study: prevalence and clinical features of impulse control disorders in Parkinson’s disease. J Neurol Neurosurg Psychiatry. 2017 Apr;88(4):317-324.

Lazzaro C, Da Deppo L, Ferrò B, Iudice A, La Neve A, Zaccara G. Cost Of Illness Of Partial Onset Seizures Epilepsy In Italy: Results From The Prometeo Study. Abstract Volume 19, ISSUE 7, PA429, November 01, 2016.

Renda G, Patti G, Sangiuolo R, Attena E, Malpezzi MG, De Caterina R; a nome dello Steering Committee del Registro Europeo PREFER in AF. Management of thromboembolic risk in patients with atrial fibrillation in Italy: follow-up data from the PREFER in AF European Registry. G Ital Cardiol (Rome). 2016 Nov;17(11):922-931

Epis OM, Casu C, Belloli L et al. Pixel or Paper? Validation of a Mobile Technology for Collecting Patient-Reported Outcomes in Rheumatoid Arthritis. JMIR Res Protoc. 2016 Nov 16;5(4):e219.

Perucca E. PROMETEO: a prospective observational study to assess the treatment effect after introduction of a different AED in patients with partial epilepsy fulfilling the 2010 ILAE criteria of drug-resistant epilepsy. 12th European Congress on Epileptology. Prague Sep 2016.

Ricci E. The management of chronic ulcers with an acidoxidising solution. J Wound Care. 2016 Aug;25(8):443-50.

Ardizzone S, Bevivino G, Monteleone G. Mongersen, an oral Smad7 antisense oligonucleotide, in patients with active Crohn’s disease. Therap Adv Gastroenterol. 2016 Jul;9(4):527-32.

Galimberti. CA. Studio Prometeo–Risultati finali. 39°Congresso Nazionale Lega Italiana Contro l’Epilessia. Roma, 8 –10 Giugno 2016.

Monteleone G, Di Sabatino A, Ardizzone S, Pallone F, Usiskin K, Zhan X, Rossiter G, Neurath MF. Impact of patient characteristics on the clinical efficacy of mongersen (GED-0301), an oral Smad7 antisense oligonucleotide, in active Crohn’s disease. Aliment Pharmacol Ther. 2016 Mar;43(6):717-24.

Prantera C. Orchard T. Prevalence of Extraintestinal manifestations in Inflammatory Bowel Disease in Italy: The ISPEM study. CPT Orchard – Researchgate.net (Oct 2015).

Frisinghelli A, Cesana F, Clavario P et al. Italian cardiologists and tobacco smoking. A survey on the prevalence and knowledge of smoking and strategies for smoking cessation in a cohort of Italian cardiologists. G Ital Cardiol 2015;16: 426-432.

Mecarelli O, Michelucci R, Ferrò B, Perucca E per conto dello Study Group Prometeo SP0992. PROMETEO: Analisi preliminare ad interim di uno studio osservazionale prospettico per valutare l’effetto dell’introduzione di un differente farmaco antiepilettico (FAE) in pazienti con epilessia focale rispondenti ai criteri di farmaco resistenza ILAE 2010. 38° Congresso Nazionale Lega Italiana Contro l’Epilessia. Genova, Giugno 2015.

Cordella C; Oliveri E; Sonnati M; Barabino S. A New iPad and iPhone App to Manage Patients with Dry Eye. ARVO Annual Meeting Abstract | June 2015 Volume 56, Issue 7.

Monteleone G, Neurath MF, Ardizzone S, Di Sabatino A, Fantini MC, Castiglione F, Scribano ML, Armuzzi A, Caprioli F, Sturniolo GC, Rogai F, Vecchi M, Atreya R, Bossa F, Onali S, Fichera M, Corazza GR, Biancone L, Savarino V, Pica R, Orlando A, Pallone F. Mongersen, an oral SMAD7 antisense oligonucleotide, and Crohn’s disease. N Engl J Med. 2015 Mar 19;372(12):1104-13.

De Caterina R, Ammentorp B, Darius H, Le Heuzey JY, Renda G, Schilling RJ, Schliephacke T, Reimitz PE, Schmitt J, Schober C, Zamorano JL, Kirchhof P; PREFER in AF Registry Investigators. Frequent and possibly inappropriate use of combination therapy with an oral anticoagulant and antiplatelet agents in patients with atrial fibrillation in Europe. Heart. 2014 Oct;100(20):1625-35.

Palumbo A, Cavallo F, Gay F, Di Raimondo F, Ben Yehuda D, Petrucci MT, Pezzatti S, Caravita T, Cerrato C, Ribakovsky E, Genuardi M, Cafro A, Marcatti M, Catalano L, Offidani M, Carella AM, Zamagni E, Patriarca F, Musto P, Evangelista A, Ciccone G, Omedé P, Crippa C, Corradini P, Nagler A, Boccadoro M, Cavo M. Autologous transplantation and maintenance therapy in multiple myeloma. N Engl J Med. 2014 Sep 4;371(10):895-905.

Barabino S, Rolando M, Nardi M, Bonini S, Aragona P, Traverso CE. The effect of an artificial tear combining hyaluronic acid and tamarind seeds polysaccharide in patients with moderate dry eye syndrome: a new treatment for dry eye. Eur J Ophthalmol. 2014 Mar-Apr;24(2):173-8.

De Caterina R, Renda G, Sangiuolo R, Attena E, Di Lecce L, Romeo F; Steering Committee del Registro Europeo PREFER in AF. Management of thromboembolic risk in patients with atrial fibrillation in Italy: baseline data from the PREFER in AF European Registry. G Ital Cardiol (Rome). 2014 Feb;15(2):99-109.

Zorzi F, Calabrese E, Monteleone I, et al. A phase 1 open-label trial shows that smad7 antisense oligonucleotide (GED0301) does not increase the risk of small bowel strictures in Crohn’s disease. Aliment Pharmacol Ther. 2012 Nov;36(9):850-7.

Monteleone G, Fantini MC, Onali S Zorzi F, Sancesario G, Bernardini S, Calabrese E, Viti F, Monteleone I, Biancone L, Pallone F. Phase I clinical trial of Smad7 knockdown using antisense oligonucleotide in patients with active Crohn’s disease. Mol Ther. 2012 Apr;20(4):870-61.

Fiocchi A, Omboni S, Mora R, Macchi A, Nespoli L, Arrigoni S, Guastini L, Castelnuovo P, Graziani D, Marcassa S. Efficacy and safety of ribosome-component immune modulator for preventing recurrent respiratory infections in socialized children. Allergy Asthma Proc. 2012 Mar-Apr;33(2):197-204

Zaim M, Piselli L, Fioravanti P et al. Efficacy and tolerability of a prolonged release ferrous sulphate formulation in iron deficiency anaemia: a non-inferiority controlled trial. Eur J Nutr. 2012 Mar;51(2):221-9.

Neuzillet Y, Naber KG, Schito G, Gualco L, Botto H. French results of the ARESC study: clinical aspects and epidemiology of antimicrobial resistance in female patients with cystitis. Implications for empiric therapy. Med Mal Infect. 2012 Feb;42(2):66-75.

Costabel U, Bonella F. Treatment of pulmonary fibrosis. New substances and new interventions. Internist (Berl). 2011 Dec;52(12):1422-8.

Chlabicz S, Leszczynska K, Lukas W, Gualco L, Schito G, Naber KG. Uncomplicated lower urinary tract infections in females–clinical aspects, aetiology and antimicrobial resistance epidemiology. Results of the ARESC (Antimicrobial Resistance Epidemiological Survey on Cystitis) study in Poland and their implications for empiric therapy. Przegl Epidemiol. 2011;65(2):345-51.

Perepanova TS, Siniakova LA, Zaĭtsev AV, Kozlov RS, Shevelev AN, Gualco L, Achito G, Naber KG. Russian results of the international epidemiological study of clinical aspects and resistance to antimicrobial medicines of cystitis uropathogens in females (ARESC): significance of empiric therapy. Urologiia. 2011 Mar-Apr;(2):30-6.

Schito GC, Gualco L, Naber KG, Botto H, Palou J, Mazzei T, Marchese A. Do different susceptibility breakpoints affect the selection of antimicrobials for treatment of uncomplicated cystitis? J Chemother. 2010 Oct;22(5):345-54.

Rolando M, Bonini S, Aragona- P, Modorati GM, Barabino S. Lacrima. The Italian Register of Patients with Tear Dysfunction. TFOS (Tear Film and Ocular Surface), Florence 23-25 sept 2010. (poster).

Wagenlehner FM, Wagenlehner C, Savov O, Gualco L, Schito G, Naber KG. Clinical aspects and epidemiology of uncomplicated cystitis in women. German results of the ARESC Study. Urologe A. 2010 Feb;49(2):253-61.

Schito GC, Naber KG, Botto H, Palou J, Mazzei T, Gualco L, Marchese A. The ARESC study: an international survey on the antimicrobial resistance of pathogens involved in uncomplicated urinary tract infections. Int J Antimicrob Agents. 2009 Nov;34(5):407-13.

Behr J, Demedts M, Buhl R, Costabel U, Dekhuijzen RP, Jansen HM, MacNee W, Thomeer M, Wallaert B, Laurent F, Nicholson AG, Verbeken EK, Verschakelen J, Flower CD, Petruzzelli S, De Vuyst P, van den Bosch JM, Rodriguez-Becerra E, Lankhorst I, Sardina M, Boissard G; IFIGENIA study group. Lung function in idiopathic pulmonary fibrosis–extended analyses of the IFIGENIA trial. Respir Res. 2009 Oct 27.

Naber KG, Schito G, Botto et al. Surveillance study in Europe and Brazil on clinical aspects and Antimicrobial Resistance Epidemiology in Females with Cystitis (ARESC): implications for empiric therapy. Eur Urol. 2008 Nov;54(5):1164-75.

Thomeer M, Demedts M, Behr J, Buhl R, Costabel U, Flower CD, Verschakelen J, Laurent F, Nicholson AG, Verbeken EK, Capron F, Sardina M, Corvasce G, Lankhorst I; Idiopathic Pulmonary Fibrosis International Group Exploring N-Acetylcysteine I Annual (IFIGENIA) study group. Multidisciplinary interobserver agreement in the diagnosis of idiopathic pulmonary fibrosis. Eur Respir J. 2008 Mar;31(3):585-91. Epub 2007 Dec 5.

Equinozzi R, Robuschi M; Italian Investigational Study Group on Pholcodine in Acute Cough. Comparative efficacy and tolerability of pholcodine and dextromethorphan in the management of patients with acute, non-productive cough : a randomized, double-blind, multicenter study. Treat Respir Med. 2006;5(6):509-13.

Demedts M, Behr J, Buhl R, Costabel U, Dekhuijzen R, Jansen HM, MacNee W, Thomeer M, Wallaert B, Laurent F, Nicholson AG, Verbeken EK, Verschakelen J, Flower CD, Capron F, Petruzzelli S, De Vuyst P, van den Bosch JM, Rodriguez-Becerra E, Corvasce G, Lankhorst I, Sardina M, Montanari M; IFIGENIA Study Group. High-dose acetylcysteine in idiopathic pulmonary fibrosis. N Engl J Med. 2005 Nov 24;353(21):2229-42.

Lehmann HP,. Shortliffe EH. Information Technology Support of Clinical Research: An Introduction. December 2003, Volume 5, Issue 4, pp 415–419.